Comparative In Vitro Activities of Daptomycin and Vancomycin Against Resistant Gram-positive Pathogens

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Nov 18

PMID 11083657

Citations 25

Authors

D R Snydman

N V Jacobus

L A McDermott

J R Lonks

J M Boyce

Affiliations

Soon will be listed here.

Abstract

The in vitro activity of daptomycin against 224 current gram-positive clinical isolates including vancomycin-resistant Enterococcus faecium (VREF), methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus spp. (MRSS), and penicillin-resistant Streptococcus pneumoniae (PRSP) was evaluated. The MICs at which 90% of isolates are inhibited for daptomycin and vancomycin, respectively, were as follows: MRSA, 1 and 2 microg/ml; MRSS, 1 and 4 microg/ml; PRSP, 1 and 0.5 microg/ml; and VREF, 2 and >64 microg/ml. Daptomycin was bactericidal against 82% of 17 VREF isolates. The antibacterial activity of daptomycin was strongly dependent on the calcium concentration of the medium. Daptomycin was active against all gram-positive cocci tested.

Citing Articles

Identification of mutants with increased daptomycin resistance.

Zbylicki B, Murphy C, Petsche J, Muh U, Dobrila H, Ho T J Bacteriol. 2024; 206(3):e0036823.

PMID: 38376203 PMC: 10955854. DOI: 10.1128/jb.00368-23.

Identification of DraRS in , a Two-Component Regulatory System That Responds to Lipid II-Interacting Antibiotics.

Pannullo A, Zbylicki B, Ellermeier C J Bacteriol. 2023; 205(10):e0016423.

PMID: 37439672 PMC: 10601625. DOI: 10.1128/jb.00164-23.

HexSDF Is Required for Synthesis of a Novel Glycolipid That Mediates Daptomycin and Bacitracin Resistance in C. difficile.

Pannullo A, Guan Z, Goldfine H, Ellermeier C mBio. 2023; 14(2):e0339722.

PMID: 36786594 PMC: 10128005. DOI: 10.1128/mbio.03397-22.

Comparison of Zinc Concentrations in the Broth of Commercial Automated Susceptibility Testing Devices (Vitek 2, MicroScan, BD Phoenix, and Sensititre).

Asempa T, Gill C, Chibabhai V, Nicolau D Microbiol Spectr. 2022; 10(2):e0005222.

PMID: 35377221 PMC: 9045177. DOI: 10.1128/spectrum.00052-22.

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Das B, Sarkar C, Das D, Gupta A, Kalra A, Sahni S Ther Adv Infect Dis. 2017; 4(2):49-73.

PMID: 28634536 PMC: 5467880. DOI: 10.1177/2049936117690501.

References

Low D, McGeer A, Poon R . Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrob Agents Chemother. 1989; 33(4):585-8. PMC: 172486. DOI: 10.1128/AAC.33.4.585. View

Niu W, Neu H . Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother. 1991; 35(5):998-1000. PMC: 245145. DOI: 10.1128/AAC.35.5.998. View

Hanberger H, Nilsson L, Maller R, Isaksson B . Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991; 35(9):1710-6. PMC: 245255. DOI: 10.1128/AAC.35.9.1710. View

Goering R, Winters M . Rapid method for epidemiological evaluation of gram-positive cocci by field inversion gel electrophoresis. J Clin Microbiol. 1992; 30(3):577-80. PMC: 265112. DOI: 10.1128/jcm.30.3.577-580.1992. View

Shonekan D, Mildvan D, Handwerger S . Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992; 36(7):1570-2. PMC: 191623. DOI: 10.1128/AAC.36.7.1570. View

Lamp K, Rybak M, Bailey E, Kaatz G . In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother. 1992; 36(12):2709-14. PMC: 245533. DOI: 10.1128/AAC.36.12.2709. View

Lakey J, Ptak M . Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry. 1988; 27(13):4639-45. DOI: 10.1021/bi00413a009. View

Mobarakai N, Quale J, Landman D . Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1994; 38(2):385-7. PMC: 284464. DOI: 10.1128/AAC.38.2.385. View

Rybak M, Hershberger E, MOLDOVAN T, Grucz R . In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother. 2000; 44(4):1062-6. PMC: 89814. DOI: 10.1128/AAC.44.4.1062-1066.2000. View

10.

Eliopoulos G, Willey S, Reiszner E, Spitzer P, Caputo G, Moellering Jr R . In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986; 30(4):532-5. PMC: 176475. DOI: 10.1128/AAC.30.4.532. View

11.

Benson C, Beaudette F, Trenholm G . Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother. 1987; 20(2):191-6. DOI: 10.1093/jac/20.2.191. View

12.

Silva M, Jacobus N, Gorbach S . In vitro activity of LY146032 against gram-positive bacteria. Diagn Microbiol Infect Dis. 1988; 9(2):79-85. DOI: 10.1016/0732-8893(88)90100-9. View

13.

Lamp K, Rybak M . Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob Agents Chemother. 1993; 37(3):605-9. PMC: 187715. DOI: 10.1128/AAC.37.3.605. View